PCN17 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, UK AND ITALY- BEVACIZUMAB (BEV) INTERFERON-ALPHA2A COMPARED WITH SUNITINIB
May 1, 2009, 00:00
10.1016/S1098-3015(10)73254-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)73254-X/fulltext
Title :
PCN17 COST OF MANAGING SIDE EFFECTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN GERMANY, FRANCE, UK AND ITALY- BEVACIZUMAB (BEV) INTERFERON-ALPHA2A COMPARED WITH SUNITINIB
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73254-X&doi=10.1016/S1098-3015(10)73254-X
First page :
Section Title :
Open access? :
No
Section Order :
674